`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`
`v.
`
`CIPLA LTD.,
`Patent Owner.
`
`Patent No. 8,168,620
`Issue Date: May 1, 2012
`Title: COMBINATION OF AZELASTINE AND STEROIDS
`
`
`
`
`Inter Partes Review No.: IPR2017-00807
`
`
`
`
`
`PETITIONER’S RESPONSE TO PATENT OWNER’S
` MOTION FOR OBSERVATIONS ON CROSS-EXAMINATION OF
`PETITIONER’S REPLY WITNESSES: DR. ROBERT SCHLEIMER, DR.
`MAUREEN DONOVAN, AND JOHN C. STAINES, JR
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Petitioner Argentum Pharmaceuticals LLC (“Petitioner”) hereby responds to
`
`Patent Owner’s motion for observations regarding the cross-examinations of Dr.
`
`Robert Schleimer, Dr. Maureen Donovan, and John C. Stains, Jr. (Paper 44,
`
`hereafter “Mot.”). Office Patent Trial Practice Guide, 77 Fed. Reg. 48756 at
`
`48767-68 (August 14, 2012).
`
`Observation #1: Patent Owner’s assertion that Dr. Schleimer’s testimony is
`
`undermined by his adoption of the statements in footnote 1 of his second
`
`declaration (EX1144) misapprehends the deposition testimony and the claims.
`
`Footnote 1 made clear that Dr. Schleimer did not consider the specific limitations
`
`of claims 4 and 42-44 because “[Petitioner] asked a formulation expert to weigh in
`
`on them,” and that otherwise Dr. Schleimer considers “the combination of
`
`azelastine and fluticasone in a formulation suitable for nasal administration to be
`
`obvious for claims 4 and 42-44 for the same reasons as all the claims discussed [in
`
`the declaration].” EX1144, n.1. Claims 4 and 42-44 all depend from claim 1,
`
`making Dr. Schleimer’s opinions as to claim 1 relevant to claims 4 and 42-44.
`
`Observation #2: Patent Owner’s assertions misapprehend Dr. Schleimer’s
`
`deposition testimony. Dr. Schleimer explained that from a layperson’s perspective,
`
`the clinical practice of conjunctive therapy most closely approximates the claimed
`
`invention. EX2179, 42:17-44:17. Dr. Schleimer also recognized that in the
`
`context of this legal proceeding where “prior art” might be restricted to printed
`
`
`
`1
`
`
`
`
`
`publications only, Segal and Cramer would be the strongest prior art. Id. Dr.
`
`Schleimer also noted that adoption of that prior art “does change [his] opinion”
`
`relative to his layman consideration of prior clinical use. Id.
`
`Observation #3: Patent Owner’s assertions based on Dr. Schleimer’s
`
`testimony regarding Howarth and Nielsen both mischaracterize his testimony and
`
`ignore other relevant testimony. As to Howarth (EX2041), Dr. Schleimer
`
`explained that Howarth’s assertion of lack of clinical benefit was unsupported, and
`
`that Howarth overlooked the additivity of azelastine and fluticasone during the first
`
`two weeks of administration (EX2179, 66:2-20),which Dr. Schleimer explained in
`
`greater detail in his declaration (EX1144, ¶¶32-36). Regarding Nielsen (EX2042),
`
`Dr. Schleimer explained that the authors’ goal was to “definitively establish that
`
`steroids are superior to antihistamines, but when it came to discussing the
`
`combination, they kind of gave it short shift” and that “they begrudgingly admit
`
`that the combination has some marginal benefits but the cost is an issue” (EX2179,
`
`73:6-9, 12-15), which was also discussed in more detail in Dr. Schleimer’s
`
`declaration (EX1144, ¶¶37-38). Dr. Schleimer also noted that one of Cipla’s own
`
`experts disagreed with the conclusions of these papers. Id., ¶39.
`
`Observation #4: Patent Owner’s assertions regarding what Dr. Schleimer
`
`explained in relation to Ratner 2008 (EX1045) grossly mischaracterizes the
`
`deposition testimony. The testimony ascribed to Dr. Schleimer only occurred
`
`
`
`2
`
`
`
`
`
`when he was asked to read aloud a quote from Ratner 2008 (EX2179, 96:13-19)—
`
`this was not Dr. Schleimer’s own testimony regarding Ratner. Instead, when asked
`
`“doesn’t this statement imply that six years later the authors were surprised by the
`
`efficacy of their regimen?” Dr. Schleimer explained that “[t]o me, as I've testified,
`
`a POSA would have anticipated an additivity, and a POSA would have looked at
`
`these results and thought, yeah, that makes sense” and “[w]hy they wrote it’s
`
`unanticipated and to what extent it truly reflects the views of all the authors, I
`
`cannot comment.” Id., 98:2-21.
`
`Observation #5: Patent Owner’s assertions that Dr. Schleimer relied on
`
`post-invention publications to support his obviousness conclusions mischaracterize
`
`the testimony and ignores other relevant testimony. Dr. Schleimer testified that it
`
`was well-known before the priority date that azelastine’s onset was 15-30 minutes.
`
`EX2179, 103:15-104:11, 109:11-13. Dr. Schleimer then explained that because
`
`Dr. Carr affirmatively contested the fast onset of azelastine, he felt it was important
`
`to find support both before and after the priority date showing that Dr. Carr’s
`
`arguments were incorrect. Id., 104:19-105:22.
`
`Observation #6: Patent Owner’s assertion that Dr. Donovan undermined
`
`her credibility when she stood by her trial demonstratives is false. Dr. Donovan
`
`explained that the purpose of the chart in EX2177 was not to communicate to the
`
`Court the advantages and drawbacks of all of the tonicity agents shown. EX2178,
`
`
`
`3
`
`
`
`
`
`55:11-18. Dr. Donovan also testified on numerous occasions regarding the fact
`
`that while all of the listed materials were obvious tonicity agents, there were
`
`advantages to glycerine and drawbacks to sodium chloride and dextrose that would
`
`cause a POSA to prefer glycerine over the other choices. EX2178, 44:16-45:5;
`
`45:17-46:3; 54:15-55:6; 56:1-19; see also EX1145, ¶¶68-70 (same).
`
`Observation #7: Patent Owner’s assertion that Dr. Donovan’s deposition
`
`testimony contradicts her testimony that a motivation existed to “use the three
`
`preservatives as recited in claims 42-44” and to “avoid using dextrose”
`
`mischaracterizes the testimonial record. When asked if there was no need for
`
`dextrose when using the preservatives from Flonase in a combination fluticasone
`
`azelastine formulation, Dr. Donovan testified that a “POSA always holds out the
`
`possibility that they will have some undesired failure of their system and then the
`
`dextrose will serve as a great growth media.” EX2178, 66:20-67:13. Dr.
`
`Donovan’s declaration also explains that “[s]ugars like dextrose are known for
`
`aiding bacterial growth when used in low concentrations.” EX1145, ¶69. This is
`
`further corroborated by Dr. Donovan in her deposition. EX2178, 71:18-72:7.
`
`Additionally, Dr. Donovan also testified that there is “always a concern that your
`
`antimicrobial preservatives will fail under some use challenge” and that one can
`
`“address that concern through the use of adequate antimicrobial preservatives.”
`
`Id., 67:4-9; 73:5-8.
`
`
`
`4
`
`
`
`
`
`Observation #8: Patent Owner’s assertion that Dr. Donovan’s deposition
`
`testimony relating to whether two amine structures in azelastine are tertiary amines
`
`undercuts her testimony that azelastine is a monovalent cation misapprehends the
`
`testimony. Dr. Donovan testified that azelastine contains only one functional
`
`group that would be characterized as a tertiary amine. EX2178, 124:7-125:1;
`
`126:5-8, 16-19. Dr. Donovan also testified that unless the pH were extreme (e.g.,
`
`below 0 or 1, or near 14 and above), azelastine contains only a single protonation
`
`site. Id., 128:16-130:1. In her declaration, Dr. Donovan also referenced Dr.
`
`Smyth’s opinion that “[i]n a pharmaceutical aqueous solution, the tertiary amine of
`
`azelastine will have a [singular] positive charge,” which translates to azelastine
`
`behaving like a monovalent cationic drug in solution. EX1145, ¶28; EX2150, ¶47.
`
`The testimony highlighted by Patent Owner relates to counsel’s questions asking
`
`what the other two amines in azelastine would be called, i.e., what technical term
`
`would be used to describe those other functional groups. EX2178, 125:12-16.
`
`That issue was not within the scope of Dr. Donovan’s testimony or expertise (id.,
`
`126:1-4, 15-16), nor is it relevant.
`
`Observation #9: Dr. Donovan’s testimony that a final formulation must
`
`administer the dose that was intended to be administered is irrelevant to her
`
`disagreement with Dr. Smyth’s construction of a “dosage form that is suitable for
`
`nasal administration.” Dr. Donovan testified that a dosage form is suitable for
`
`
`
`5
`
`
`
`
`
`nasal administration if it is able to administer the dose that was intended to be
`
`administered and to do so, a POSA would use chemical analysis to determine the
`
`amount of drug the spray was delivering. EX2178, 138:19-139:2; 163:21-164:17.
`
`Dr. Donovan’s testimony does not support Dr. Smyth’s proffered claim
`
`construction of “pharmaceutical formulations that are tolerable to patients, that are
`
`homogeneous, and that can be suitably deposited on the nasal mucosa.” Dr.
`
`Donovan’s declaration explains in detail that Dr. Govindarajan’s recreations of
`
`Cramer Example III were physically stable and provided a successful nasal spray,
`
`which were the relevant issues with respect to these tests. EX1145, ¶¶34-40.
`
`Observation #10: Patent Owner’s assertion that Dr. Donovan conceded that
`
`Dr. Govindarajan’s recreations of Cramer Example III were not a “dosage form
`
`suitable for a nasal administration” is a misstatement of the record. Dr. Donovan’s
`
`declaration explains in detail that Dr. Govindarajan’s recreations “could be
`
`delivered as a fine spray using a nasal spray pump.” EX1145, ¶40. Dr. Donovan
`
`testified that Dr. Govindarajan’s first recreation of Cramer Example III was “his
`
`first mixing of materials” in response to a question on whether visual observation
`
`“doesn’t foreclose the possibility that the composition is not uniformly
`
`resuspended.” EX2178, 197:11-198:9. Dr. Donovan further explained that each of
`
`the three batches Dr. Govindarajan recreated were found to be physically stable
`
`and exhibited behaviors of a pharmaceutically acceptable suspension. EX1145,
`
`
`
`6
`
`
`
`
`
`¶¶34, 40. The relevance of Dr. Govindarajan’s recreations of Cramer Example III
`
`relates only to the fact that the formulations were adequately suspended and stable,
`
`and could be adequately sprayed, not whether they were in a “dosage form suitable
`
`for a nasal administration.” Dr. Donovan was never asked at her deposition and
`
`never testified that Dr. Govindarajan’s recreations of Cramer Example III were not
`
`in a “dosage form suitable for a nasal administration.”
`
`Observation #11: Patent Owner’s assertion that Dr. Donovan did not “call
`
`into question” in the related district court proceeding the difference in the grades of
`
`viscosity of HPMC used by Drs. Herpin and Govindarajan mischaracterizes the
`
`testimonial record. Dr. Donovan testified that she “was certainly aware of” the
`
`HPMC viscosity grade difference for the Apotex case, but simply could not “recall
`
`a paragraph that speaks directly to the viscosity grade of the HPMC.” EX2178,
`
`172:19-173:10; 174:6-9. Dr. Donovan denied the suggestion that this issue was
`
`not meaningful enough to point out in her reply report in the Apotex case. Id.,
`
`173:20-22. Instead, Dr. Donovan testified repeatedly that the Apotex case involved
`
`other issues, other experts, was “a different litigation.” Id., 173:8-10, 14-19;
`
`174:19-175:3.
`
`Observation #12: Patent Owner’s assertion that Dr. Donovan’s testimony
`
`regarding azelastine dissociating into electrolytes undercuts her conclusion that
`
`azelastine hydrochloride would not have been viewed by a POSA as incompatible
`
`
`
`7
`
`
`
`
`
`with MCC/CMC is false and unsupported by the testimonial record. Dr.
`
`Donovan’s declaration explains that azelastine hydrochloride would be understood
`
`to dissociate to a monovalent cation in an aqueous media. EX1145, ¶28. Dr.
`
`Donovan also testified only that cations and anions are “broadly classified as
`
`electrolytes.” EX2178, 120:4-7. As to the compatibility of azelastine
`
`hydrochloride with MCC/CMC, Dr. Donovan explained in her declaration that
`
`MCC/CMC are compatible with monovalent cationic drugs like azelastine.
`
`EX1145, ¶¶18-29. Patent Owner cites no other evidence to support its conclusion
`
`in this observation, nor is any connection apparent.
`
`Observation #13: Patent Owner’s assertion that Dr. Donovan admitted that
`
`the two-preservative combinations in Astelin® and Flonase® were sufficient to
`
`inhibit bacterial growth mischaracterizes the deposition testimony. Dr. Donovan
`
`testified that there is “always a concern that your antimicrobial preservatives will
`
`fail under some use challenge,” and that one can “address that concern through the
`
`use of adequate antimicrobial preservatives.” EX2178, 67:4-9; 73:5-8. Dr.
`
`Donovan further explains in her declaration why a POSA would have been
`
`motivated to select the three preservatives used at issue here. EX1145, ¶¶59-66.
`
`Observation #14: Patent Owner’s assertion that Dr. Donovan’s failure to
`
`rely on “prior art” to support a pH of 3 or below being “suitable for nasal
`
`administration” speaks to the weight and credibility of Dr. Donovan’s conclusions
`
`
`
`8
`
`
`
`
`
`is without merit. Dr. Donovan cites both to claim 45 of the ’620 patent as well as
`
`Dr. Smyth’s own deposition testimony to support her conclusion that a pH of 3 or
`
`below is suitable for nasal administration. EX1145, ¶46; EX1143, 79:9-20;
`
`EX1001, claims 1, 45.
`
`Observation #15: Patent Owner’s assertion that Dr. Donovan “admitted that
`
`Dr. Govindarajan’s visual observations alone are insufficient to show a uniform
`
`suspension” misstates the testimonial record. Dr. Donovan never testified that
`
`visual observations alone are insufficient to show a uniform suspension. Dr.
`
`Donovan testified that she would “use whatever information I'm provided and
`
`discern whether I think it makes logical sense.” EX2178, 196:21-197:1. She
`
`further testified that when recreating Cramer Example III, Dr. Govindarajan used a
`
`methodology entirely consistent with how she believes a POSA would approach
`
`the problems he was given, and that she has no reason to not believe the notations
`
`Dr. Govindarajan recorded. EX2178, 197:2-9. Dr. Donovan also testified that a
`
`chemical analysis is “not what one does with the first formulation mixing attempt
`
`that you undertake as a formulation development scientist.” Id., 197:17-198:9; see
`
`also 195:6-8. Lastly, Dr. Donovan testified that she was “willing to believe” that
`
`Dr. Govindarajan readily and uniformly resuspended the solid. Id., 196:3-9.
`
`Observation #16: Patent Owner’s assertion that Mr. Staines’ deposition
`
`testimony undercuts his credibility and undermines “his conclusions that rebates
`
`
`
`9
`
`
`
`
`
`and copayment programs were primary drivers of Dymista® sales”
`
`mischaracterizes the testimonial record. Mr. Staines’ declaration explains in detail
`
`how rebates and copayment programs resulted in low net prices for Dymista, and
`
`that analysis does not rely on identification of specific portions of sales. EX1040,
`
`¶¶119-125. As to impact of Dymista rebates, and comparison to other drugs, Mr.
`
`Staines testified that he analyzed Dymista’s rebates using documentation and his
`
`experience (EX2180, 15:15-16:4), which can be found in his declaration at
`
`paragraphs 63 and 124, and Ex. 2a. Similarly, Mr. Staines testified about the
`
`impact of Dymista’s copayment program including the existence of other common
`
`copayment programs that do not reduce prices to those close to generics. EX2180,
`
`22:19-24:14.
`
`Observation #17: Patent Owner’s assertion that Mr. Staines conceded that
`
`documents he relied upon did not provide support for his assertions regarding
`
`constraints of Meda’s salesforce in paragraph 127 of his declaration
`
`mischaracterizes the deposition testimony. Paragraph 127 specifically references
`
`the 2015 GlobalData study (EX2053), and Mr. Staines specifically recited that
`
`study when asked “what was your basis for characterizing Mr. Jarosz's opinions as
`
`being limited to primary care physicians?” See EX2180, 36:2-37:19. While Mr.
`
`Staines acknowledged there was no explicit statement in EX2053 regarding
`
`Primary Care Physicians, he explained there is an inference that “if [Meda] have a
`
`
`
`10
`
`
`
`
`
`good presence with respiratory market, that means that [in] the other market,
`
`[Meda] doesn’t.” EX2180, 39:13-15.
`
`Observation #18: Patent Owner’s assertion that Mr. Staines’ deposition
`
`testimony relating to the 2012 and 2013 Dymista discount rates “under cuts Mr.
`
`Staines’ credibility and undercuts his conclusions that Dymista’s 47% rebate in
`
`2015 is atypical” misapprehends the deposition testimony relative to Mr. Staines’
`
`declaration. Mr. Staines stated in his declaration that “[t]he discounts through
`
`2015, however, are comparatively large for brand drugs,” not that those in 2012
`
`and 2013 were atypical. EX1040, ¶124. As for “atypical,” Mr. Staines specifically
`
`testified that the “47% discount is atypically large for innovative brand
`
`pharmaceuticals that have no bioequivalent generic competitors.” EX1040, ¶63.
`
`Observation #19: Patent Owner’s assertion regarding Mr. Staines’
`
`deposition testimony relating to blocking patents misapprehends the testimony
`
`relative to Mr. Staines’ declaration. Mr. Staines’ statement that the ultimate
`
`opinion as to blocking “is not my opinion” is consistent with his declaration, which
`
`explains the basis of his assumption that the blocking patents existed. EX1040,
`
`¶108. Consistent with his declaration, Mr. Staines testified “[i]t’s possible that [the
`
`blocking patents] could [block]. I could foresee that they would inhibit or impede
`
`somebody from developing a product if they’re not sure when somebody is going
`
`
`
`11
`
`
`
`
`
`to launch or when they’re going to be able to launch, and that would be an
`
`impediment or disincentive to develop.” EX2180, 89:21-90:5.
`
`Observation #20: Patent Owner’s assertions regarding Mr. Staines’
`
`testimony relating to “novel features” misapprehends his deposition testimony and
`
`the testimony provided in his declaration. Regarding “novel features,” Mr. Staines
`
`explained that “when I say something is novel, I’m using it in a layman’s sense”
`
`and that “to the extent that ‘novel’ has some patent law implication here, I’m not
`
`using it in that sense, and I don’t have an opinion in that way.” EX2180, 86:1-7.
`
`This is consistent with his declaration which states “[i]n other words, there must be
`
`a causal correlation, or ‘nexus,’ between the purported merits of the claimed
`
`invention and the success of the product,” where Mr. Staines testified during his
`
`deposition that he assumed “all the features of Dymista are in some way or form
`
`claimed in the patent, but I don’t have a technical knowledge of what specific
`
`things.” EX1140, ¶106; EX2180, 85:7-11.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`12
`
`
`
`
`
`Dated: April 24, 2018
`
`
`
`
`
`
`
`
`
`By: /Michael R. Houston/
`Michael Houston
`Registration No. 58,486
`FOLEY & LARDNER LLP
`321 North Clark Street, Suite 2800
`Chicago, Illinois 60654
`Telephone: 312-832-4500
`Facsimile: 312-832-4700
`mhouston@foley.com
`
`Counsel for Petitioner
`Argentum Pharmaceuticals LLC
`
`
`
`13
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing
`
`PETITIONER’S RESPONSE TO PATENT OWNER’S MOTION FOR
`
`OBSERVATIONS ON CROSS-EXAMINATION OF PETITIONER’S
`
`REPLY WITNESSES: DR. ROBERT SCHLEIMER, DR. MAUREEN
`
`DONOVAN, AND JOHN C. STAINES, JR was served on April 24, 2018, on
`
`Counsel for Patent Owner via electronic mail to the following:
`
`
`
`
`
`Dated: April 24, 2018
`
`dvarughe-PTAB@skgf.com
`dsterlin-PTAB@skgf.com
`alarock-PTAB@skgf.com
`ueverett-PTAB@skgf.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: /Michael R. Houston/
`Michael Houston
`Registration No. 58,486
`Counsel for Petitioner
`
`
`
`
`
`
`